Vmbook Online ordering

Alexion Pharmaceuticals Inc

Sure, I can assist you with that. Alexion Pharmaceuticals, Inc. is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol ALXN. Alexion Pharmaceuticals, Inc. develops and commercializes life-transforming therapies for rare diseases.

As of December 2022, the company's market capitalization was approximately $26.62 billion USD.

Alexion's flagship product is Soliris (eculizumab), a first-in-class terminal complement inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare, and life-threatening genetic disorders.

Alexion has been investing in clinical trials and research and development to expand its pipeline and label expansions, including those for generalized myasthenia gravis (GMG) and neuromyelitis optica (NMO), to further enhance Soliris' effectiveness and safety profile. These endeavors hold tremendous potential for the long-term growth of Alexion.

Alexion's product candidate portfolio includes ULTOMIRIS (ravulizumab-cwvz), which is approved in theUnited States, the European Union, and Japan for the treatment of adult patients with PNH, and in the United States for the treatment of adults and children with aHUS.

In December 2020, Alexion was acquired by AstraZeneca, a leading pharmaceutical company, further solidifying its commitment to transforming lives through innovative medicines.

Please note that the information I provided is general and may not reflect the company's current state or performance. It's essential to consult reputable sources or financial websites like Yahoo Finance or Seeking Alpha to get the most up-to-date information on Alexion Pharmaceuticals' financial health and market status.